How Neuropeptide Y Drives Heart Disease and Blood Disorders — And New Ways to Stop It | Research

The takeaway

Neuropeptide Y dysregulation promotes vasoconstriction, inflammation, atherosclerosis, and blood disorders through specific receptor activation, with multiple therapeutic strategies now being explored.

4 receptor subtypes
NPY acts through Y1, Y2, Y4, and Y5 receptors, with Y1 driving the harmful vasoconstriction and inflammation that contributes to heart disease

What the researchers found

Neuropeptide Y (NPY), a 36-amino-acid peptide, plays a dual destructive role in cardiovascular and blood diseases when dysregulated. In the cardiovascular system, excessive NPY signaling through Y1 receptors promotes vasoconstriction, inflammation, atherosclerosis, heart failure, and hypertension. In blood disorders, NPY influences blood cell production (hematopoiesis), immune cell activity, and blood vessel formation, contributing to thrombosis and leukemia.

The review identifies multiple therapeutic strategies targeting NPY: receptor-specific agonists and antagonists (e.g., [Leu31,Pro34]NPY, BAY 53-6206), enzyme inhibitors (DPP4 and NEP inhibitors that affect NPY breakdown), and natural substances (flavonoids, polyphenols, saponins) that modulate NPY activity.

Why it matters

NPY is one of the most abundant neuropeptides in the body, yet its role in cardiovascular and blood diseases has been overlooked compared to its better-known functions in appetite and stress. This review connects the dots: the same peptide that controls your hunger and stress response also drives blood vessel constriction, inflammation, and abnormal blood cell behavior. Understanding NPY's receptor-specific effects (Y1 vs Y2 vs Y4 vs Y5) could enable targeted therapies that modulate harmful NPY signaling without disrupting its beneficial roles.

The numbers in context

36 amino acids · 4 receptor subtypes (Y1, Y2, Y4, Y5) · Y1 activation → vasoconstriction/inflammation · multiple therapeutic approaches reviewed · DPP4 and NEP enzyme inhibitors identified · natural substance modulators cataloged

How the study worked

Comprehensive literature review examining NPY-mediated mechanisms in cardiovascular diseases and hematological disorders. Covers NPY receptor pharmacology, signaling pathways, disease mechanisms, and therapeutic strategies including synthetic analogs, receptor-specific agents, enzyme inhibitors, and natural substances.

Who was studied

Review covering preclinical and clinical research on NPY in cardiovascular and hematological disorders

What this study cannot tell us

Narrative review without systematic methodology. Most therapeutic approaches discussed are preclinical with limited clinical data. The complexity of NPY signaling across four receptor subtypes makes predicting clinical outcomes difficult. Natural substance modulators typically have weaker and less specific effects than synthetic agents. Therapeutic resistance is acknowledged but not deeply addressed.

How to read the evidence

Moderate — comprehensive review synthesizing a large body of preclinical evidence on NPY in cardiovascular and blood diseases. The receptor biology is well-established, but most therapeutic approaches remain in early stages. The strength lies in integrating evidence across cardiovascular and hematological domains.

When this study was published

Published in 2026. This is a very current review reflecting the latest understanding of NPY in cardiovascular and hematological disorders, including up-to-date therapeutic strategies.

The bigger picture

NPY connects three major health domains: metabolism (appetite, obesity), mental health (stress, anxiety, PTSD), and cardiovascular disease. This review adds a fourth — blood disorders. The interconnection explains why metabolic syndrome, stress, and heart disease so often co-occur: they share NPY as a common peptide driver. As drug developers increasingly target NPY receptors for specific diseases, understanding the full scope of NPY's effects is critical for predicting both benefits and risks.

Questions still open

Could Y1 receptor antagonists become a new class of cardiovascular drugs that reduce NPY-driven vasoconstriction and inflammation?
Do existing DPP4 inhibitors (used for diabetes) have unrecognized cardiovascular effects through modulating NPY levels?
Can natural substances like flavonoids meaningfully modulate NPY signaling at dietary doses?

Common questions

What is neuropeptide Y and what does it normally do?

NPY is a 36-amino-acid peptide found throughout your brain and nervous system. It's one of the most abundant neuropeptides in the body. Normally, it helps regulate appetite (it's one of the strongest hunger signals), manages stress responses, and fine-tunes cardiovascular function. Problems arise when NPY signaling becomes overactive, driving blood vessel constriction, inflammation, and disease.

Why target NPY for heart disease when we already have blood pressure drugs?

Current blood pressure drugs address symptoms (lowering pressure) but don't target the underlying inflammatory and vascular remodeling processes that drive disease progression. NPY-targeted therapies could address the root cause — the peptide-driven inflammation and vasoconstriction that damage blood vessels over time. Additionally, NPY drugs could potentially treat the overlap between metabolic, stress, and cardiovascular diseases since NPY connects all three.

Read the original research

Targeting Neuropeptide Y: Novel Approaches to the Treatment of Cardiovascular and Haematological Disorders.

Cardiovascular & hematological disorders drug targets

View on PubMed ↗Publisher’s paper ↗

Citation

Rahangdale, Nikita D; Thombre, Kalyani R; Gupta, Krishna R; Umekar, Milind J. (2026). Targeting Neuropeptide Y: Novel Approaches to the Treatment of Cardiovascular and Haematological Disorders.. Cardiovascular & hematological disorders drug targets. https://doi.org/10.2174/011871529X401261251128055509